5:47 PM
 | 
Mar 24, 2010
 |  BC Extra  |  Clinical News

Human Genome reports once-monthly Zalbin data

Human Genome Sciences Inc. (NASDAQ:HGSI) reported interim data from a Phase IIb trial of once-monthly Zalbin albinterferon alfa-2b in treatment-naive patients with HCV genotype 2 or 3. Daily oral ribavirin plus...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >